Generation Uranium Inc. (V:GEN*CA)

Business Focus: Specialty Mining & Metals (NEC)

Apr 12, 2024 06:30 am ET
Generation Uranium Announces the Upsizing of the Private Placement and the Closing of $1,000,000 in First Tranche
Vancouver, British Columbia, Canada – TheNewswire - April 12, 2024 – Generation Uranium Inc. (the “Company” or “Generation”), (TSXV:GEN) is pleased to announce that it has increased the size of its non-brokered private placement (the "Private Placement" or “Offering”) of 4,000,000 Units, made public on SEDAR on March 15, 2024, to 5,000,000 Units for anticipated aggregate proceeds of CAD$1,250,000. The first of two tranches of the Private Placement closed with the issuance of 4,000,000 Units, each consisting of one Common Share of the Company and one Common Share Purchase Warrant at a price of
Apr 11, 2024 04:00 pm ET
Generation Uranium Announces the Upsizing of the Private Placement and the Closing of $1,000,000 in First Tranche.
Vancouver, British Columbia, Canada, April 11, 2024 – TheNewswire – Generation Uranium Inc. (the “Company” or “Generation”), (TSXV: GEN) is pleased to announce that it has increased the size of its non-brokered private placement (the "Private Placement" or “Offering”) of 4,000,000 Units, made public on SEDAR on March 15, 2024, to 5,000,000 Units for anticipated aggregate proceeds of CAD$1,250,000. The first of two tranches of the Private Placement closed with the issuance of 4,000,000 Units, each consisting of one Common Share of the Company and one Common Share Purchase Warrant at a price of
Apr 03, 2024 01:34 am ET
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel...
Mar 20, 2024 06:00 am ET
Generation Uranium to Begin Exploration Program On Its 100% Wholly Owned Yath Project in Nunavut, Canada
Vancouver, British Columbia, Canada, March 19th, 2024 – Generation Uranium Inc. (the “Company” or “Generation”), (TSXV: GEN) is pleased to announce that an inaugural exploration program will begin on its 85km², 8,500-ha property located in the Thelon Basin in Nunavut, Canada. Due to strong historical sampling and anticipated long-term elevated world spot uranium pricing due to favorable supply and demand dynamics, the Company anticipates that it will expend a significant amount of its capital resources into the basin in 2024.
Mar 15, 2024 05:00 pm ET
Generation Uranium Announces Non-Brokered Private Placement for Aggregate Proceeds of up to CAD$1,000,000
Vancouver, British Columbia, Canada / TheNewswire / March 15, 2024 – Generation Uranium Inc. (the “Company” or “Generation”), (TSXV: GEN) is pleased to announce that it intends to complete a non-brokered Private Placement of up to 4,000,000 units of the Company ("Units") at a price of $0.25 per Unit for aggregate gross proceeds of up to $1,000,000 (the "Private Placement").
Mar 15, 2024 04:00 pm ET
Generation Uranium Announces Closing of Non-Brokered Private Placement for Aggregate Proceeds of CAD$400,000
Vancouver, British Columbia, Canada / TheNewswire / March 15, 2024 – Generation Uranium Inc. (the “Company” or “Generation”), (TSXV: GEN) is pleased to announce the closing of its non-brokered Private Placement (the “Offering”) of the Company as previously announced on February 7, 2024.
Feb 14, 2024 11:41 am ET
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on March 15, 2024  COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it...
Feb 14, 2024 11:02 am ET
Genmab Publishes 2023 Annual Report
Company Announcement COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Below is a summary of business progress in 2023, financial performance for the year and the...
Nov 09, 2023 09:14 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 9, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Nov 08, 2023 11:09 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 8, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Nov 07, 2023 11:01 am ET
Genmab Announces Financial Results for the First Nine Months of 2023
November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY®) was granted conditional marketing authorization by the European Commission (EC) to treat adults with...
Oct 17, 2023 06:22 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
Company Announcement Net sales of DARZALEX® in the third quarter of 2023 totaled USD 2,499 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 17, 2023 – Genmab A/S (Nasdaq:...
Sep 25, 2023 07:45 am ET
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of...
Sep 04, 2023 03:00 pm ET
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysisTrial results to be submitted for presentation at a future medical meetingGenmab...
Aug 03, 2023 11:01 am ET
Genmab Announces Financial Results for the First Half of 2023
August 3, 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody to treat...
Jul 27, 2023 06:01 pm ET
Genmab Updates 2023 Financial Guidance
Company Announcement COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. Preliminary First Half 2023 Financial Results...
Jul 21, 2023 04:30 am ET
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with non-Hodgkin’s lymphoma (NHL), including diffuse large...
Jul 20, 2023 06:22 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
Company Announcement Net sales of DARZALEX® in the second quarter of 2023 totaled USD 2,431 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 20, 2023 – Genmab A/S (Nasdaq: GMAB)...
Jun 27, 2023 06:49 pm ET
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss next stepsData from the clinical trial will be presented at a future medical...
May 19, 2023 12:33 pm ET
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLB
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY™ (epcoritamab-bysp) delivered 61 percent overall response rate, 38 percent complete response, and 15.6-month median duration of response in challenging-to-treat R/R DLBCL...
May 10, 2023 11:01 am ET
Genmab Announces Financial Results for the First Quarter of 2023
May 10, 2023 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 35% compared to the first quarter of 2022, to DKK 2,854 million “In the first quarter of the year we continued to lay...
Apr 24, 2023 04:39 am ET
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under its license agreement with...
Apr 20, 2023 07:45 pm ET
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. The arbitral tribunal...
Apr 18, 2023 06:25 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
Company Announcement Net sales of DARZALEX® in the first quarter of 2023 totaled USD 2,264 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18, 2023 – Genmab A/S (Nasdaq: GMAB)...
Apr 17, 2023 02:00 am ET
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Media ReleaseCOPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapiesDiscovery programs against two differentiated...
Feb 22, 2023 11:12 am ET
Genmab Announces Initiation of Share Buy-Back Program
Company Announcement Repurchase of up to 220,000 sharesHonoring commitments under our Restricted Stock Unit programCompletion expected on March 31, 2023 COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that it is...
Feb 22, 2023 11:01 am ET
Genmab Publishes 2022 Annual Report
Company Announcement COPENHAGEN, Denmark; February 22, 2023 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2022. Below is a summary of business progress in 2022, financial performance for the year and the...
Jan 24, 2023 06:27 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today...
Nov 09, 2022 11:01 am ET
Genmab Announces Financial Results for the First Nine Months of 2022
November 9, 2022 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2022 Highlights Genmab revenue increased 60% compared to the first nine months of 2021, to DKK 9,368 millionGenmab improves its 2022 financial...
Nov 03, 2022 12:45 pm ET
Genmab Improves Its 2022 Financial Guidance
Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; November 3, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance published on August 8, 2022. The improved guidance...
Oct 18, 2022 06:35 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
Company Announcement Net sales of DARZALEX® in the third quarter of 2022 totaled USD 2,052 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 18, 2022 – Genmab A/S (Nasdaq:...
Oct 05, 2022 03:56 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 5, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Aug 10, 2022 11:01 am ET
Genmab Announces Financial Results for the First Half of 2022
August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory...
Aug 08, 2022 12:33 pm ET
Genmab Improves Its 2022 Financial Guidance
Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance published on May 11, 2022. The improved guidance is...
Aug 02, 2022 02:46 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; August 2, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Jul 20, 2022 01:03 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; July 20, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Jul 19, 2022 06:33 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
Company Announcement Net sales of DARZALEX® in the second quarter of 2022 totaled USD 1,986 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 19, 2022 – Genmab A/S (Nasdaq: GMAB)...
Jul 18, 2022 10:01 am ET
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-C
Company Announcement COPENHAGEN, Denmark; July 18, 2022 – Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for...
Jul 11, 2022 11:28 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; July 11, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Jul 01, 2022 10:14 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; July 1, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Jun 30, 2022 02:24 pm ET
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab...
Jun 20, 2022 10:35 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 20, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
Jun 09, 2022 05:17 pm ET
Genmab Commences New Arbitration Under License Agreement With Janssen
Company Announcement COPENHAGEN, Denmark; June 9, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab. This new arbitration...
Jun 01, 2022 12:21 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 1, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Wellington Management Group LLP has...
May 11, 2022 11:01 am ET
Genmab Announces Financial Results for the First Quarter of 2022
May 11, 2022 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2022 Highlights DARZALEX® net sales as reported by Johnson & Johnson increased 36% compared to the first three months of 2021 to USD 1,856 million, resulting in...
Apr 19, 2022 06:29 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
Company Announcement Net sales of DARZALEX® in the first quarter of 2022 totaled USD 1,856 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. COPENHAGEN, Denmark; April 19, 2022 – Genmab A/S (Nasdaq: GMAB)...
Apr 13, 2022 05:25 pm ET
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next stepsData from the clinical trial to be presented at a future medical meetingLarge...
Apr 07, 2022 07:44 pm ET
Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
Company Announcement COPENHAGEN, Denmark; April 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to...
Feb 24, 2022 06:01 am ET
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Tuesday March 29, 2022 COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the...
Feb 16, 2022 11:00 am ET
Genmab Publishes 2021 Annual Report
Genmab Publishes 2021 Annual Report Company Announcement Copenhagen, Denmark; February 16, 2022 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2021. Below is a summary of business progress in 2021, financial...
Jan 25, 2022 06:30 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
Company Announcement Net sales of DARZALEX® in 2021 totaled USD 6,023 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 25, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that...
Jan 04, 2022 09:00 am ET
Genmab and Synaffix Enter into License Agreement for ADC Technology
Media Release Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologiesGenmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and...
Nov 10, 2021 11:00 am ET
Genmab Announces Financial Results for the First Nine Months of 2021
November 10, 2021; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2021 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Genmab and Seagen Inc. (Seagen) accelerated Approval for TIVDAK™...
Nov 04, 2021 04:24 pm ET
Genmab Improves its 2021 Financial Guidance
Company Announcement Genmab improves its 2021 financial guidance COPENHAGEN, Denmark; November 4, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2021 financial guidance published on August 11, 2021. The improved...
Oct 19, 2021 06:29 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Company Announcement Net sales of DARZALEX® in the third quarter of 2021 totaled USD 1,580 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 19, 2021 – Genmab A/S (Nasdaq: GMAB)...
Sep 21, 2021 02:22 pm ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 21, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 3,969 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights...
Sep 20, 2021 05:00 pm ET
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer CellsNew Monotherapy Approved for Use in a Cancer with Limited Treatment Options COPENHAGEN, Denmark, and BOTHELL, Wash.; September...
Aug 11, 2021 11:01 am ET
Genmab Announces Financial Results for the First Half of 2021
August 11, 2021; Copenhagen, Denmark; Interim Report for the First Half of 2021 Highlights The U.S. FDA accepted for Priority Review the tisotumab vedotin Biologics License Application (BLA), for patients with recurrent or metastatic...
Jul 21, 2021 12:58 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 21, 2021 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Artisan Partners Limited Partnership...
Jul 21, 2021 06:31 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
Company Announcement Net sales of DARZALEX® in the second quarter of 2021 totaled USD 1,433 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; July 21, 2021 – Genmab A/S (Nasdaq: GMAB)...
Jun 22, 2021 10:12 am ET
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-ch
Company Announcement Janssen received European approval for DARZALEX® SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed systemic...
May 21, 2021 09:08 am ET
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Company Announcement Janssen received a positive CHMP opinion for DARZALEX® SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed systemic...
May 05, 2021 11:01 am ET
Genmab Announces Financial Results for the First Quarter of 2021
May 5, 2021; Copenhagen, Denmark; Genmab Interim Report for the First Quarter Ended March 31, 2021 Highlights Genmab and Seagen Inc. submitted tisotumab vedotin Biologics License Application (BLA) to the U.S. FDA for patients with recurrent or...
Apr 20, 2021 06:34 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
Company Announcement Net sales of DARZALEX® in the first quarter of 2021 totaled USD 1,365 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; April 20, 2021 – Genmab A/S (Nasdaq: GMAB)...
Apr 09, 2021 04:00 pm ET
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Company Announcement FDA action date is Oct 10, 2021BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark and BOTHELL, Wash.; April...
Mar 30, 2021 01:21 am ET
Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
Company Announcement Novartis receives European approval for Kesimpta® (ofatumumab) for the treatment of relapsing forms of multiple sclerosis in adults Approval follows positive opinion by European Committee for Medicinal Products for Human Use...
Feb 25, 2021 02:53 pm ET
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; February 26, 2021 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the...
Feb 23, 2021 11:05 am ET
Genmab announces initiation of share buy-back program
Company Announcement Repurchase of up to 200,000 sharesMitigating dilution from warrant exercises and honoring commitments under our Restricted Stock Unit programCompletion expected no later than June 30, 2021 COPENHAGEN, Denmark; February 23,...
Feb 23, 2021 11:00 am ET
Genmab Publishes 2020 Annual Report
Company Announcement Copenhagen, Denmark; February 23, 2021 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2020. Below is a summary of business progress in 2020, financial performance for the year and the...
Feb 22, 2021 08:00 am ET
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head...
Feb 10, 2021 04:05 pm ET
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Company Announcement Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark and BOTHELL, Wash.; Feb 10, 2021 – Genmab A/S (Nasdaq: GMAB) and...
Jan 29, 2021 12:10 pm ET
CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
Company Announcement Novartis receives positive CHMP opinion for subcutaneous ofatumumab for adult patients with relapsing forms of multiple sclerosis Opinion based on Phase 3 ASCLEPIOS I and II studies Copenhagen, Denmark; January 28, 2021 –...
Jan 26, 2021 06:45 am ET
Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
Company Announcement Net sales of DARZALEX® in 2020 totaled USD 4,190 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 26, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that...
Jan 15, 2021 02:17 pm ET
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Company Announcement DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) approved by U.S. FDA as the first and only therapy for newly diagnosed Light-chain (AL) amyloidosisAccelerated approval of DARZALEX FASPRO-based combination regimen...
Jan 13, 2021 09:20 am ET
Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
Company Announcement Genmab to receive USD 40 million milestone payment from AbbVieMilestone triggered by progress in Phase 3 study of epcoritamab in diffuse large B-cell lymphoma Copenhagen, Denmark; January 13, 2021 – Genmab A/S (Nasdaq: GMAB)...
Jan 04, 2021 02:00 pm ET
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Media Release COPENHAGEN, Denmark, Jan. 04, 2021 Initiation of a global phase 3 trial for tisotumab vedotin versus investigator’s choice chemotherapy in recurrent or metastatic cervical cancer Genmab A/S (Nasdaq: GMAB) announced today the...
Nov 24, 2020 10:40 am ET
Genmab Announces Enapotamab Vedotin Update
Company Announcement Genmab will not advance the development of enapotamab vedotinData from expansion cohorts did not meet stringent criteria for proof-of-conceptGenmab to prioritize development of other innovative product candidates...
Nov 05, 2020 08:38 am ET
Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Company Announcement First Phase 3 study of epcoritamab as part of broad clinical development plan with AbbVieDiffuse Large B-cell Lymphoma is the most common form of non-Hodgkin’s lymphoma worldwide Copenhagen, Denmark; November 5, 2020 – Genmab...
Nov 04, 2020 11:04 am ET
Genmab Announces Financial Results for the First Nine Months of 2020
November 4, 2020; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2020 Highlights Novartis granted U.S. FDA approval for Kesimpta® (ofatumumab) in relapsing multiple sclerosisJanssen and European Myeloma Network...
Oct 21, 2020 04:48 pm ET
Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
Company Announcement Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free...
Oct 13, 2020 06:41 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
Company Announcement Net sales of DARZALEX® in the third quarter of 2020 totaled USD 1,099 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 13, 2020 – Genmab A/S (Nasdaq: GMAB)...
Sep 22, 2020 05:04 pm ET
Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen
Company Announcement Copenhagen, Denmark; September 22, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to...
Sep 21, 2020 10:20 am ET
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020 Data featured in late-breaking proffered paper oral presentation  Biologics license application submission planned to support accelerated approval pathway with the FDA...
Aug 20, 2020 04:40 pm ET
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Company Announcement DARZALEX® (daratumumab) approved by U.S. FDA in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received one to three previous lines of...
Aug 20, 2020 04:06 pm ET
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
Company Announcement Novartis intends to transition availability of Arzerra® (ofatumumab) to an oncology access program for chronic lymphocytic leukemia patients in the U.S. Genmab receives USD 30 million from Novartis as payment for lost...
Aug 20, 2020 01:33 pm ET
U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
Company Announcement  Kesimpta® (ofatumumab) approved by U.S. FDA for the treatment of relapsing forms of multiple sclerosis in adultsFirst B-cell therapy that can be self-administered using Sensoready® autoinjector penApproval based on Phase III...
Aug 12, 2020 11:23 am ET
Genmab Announces Financial Results for the First Half of 2020
August 12, 2020; Copenhagen, Denmark; Interim Report for the First Half of 2020 Highlights       ·Genmab and AbbVie enter into broad oncology collaboration; USD 750 million upfront payment with total potential milestone and opt-in payments of up...
Jul 31, 2020 03:38 pm ET
Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refrac
Company Announcement Phase 3 APOLLO randomized study evaluating subcutaneous daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in relapsed or refractory multiple myeloma met the primary...
Jul 20, 2020 11:57 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 20, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Société Générale S.A. has informed us...
Jul 16, 2020 06:43 am ET
Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020
Company Announcement Net sales of DARZALEX® in the second quarter of 2020 totaled USD 901 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; July 16, 2020 – Genmab A/S (Nasdaq: GMAB)...
Jul 07, 2020 07:01 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 7, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Société Générale S.A. has informed us...
Jul 03, 2020 03:18 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 3, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Société Générale S.A. has informed us...
Jul 03, 2020 03:51 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 3, 2020 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Société Générale S.A. has informed us...
Jun 29, 2020 04:29 pm ET
Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Company Announcement Genmab and Seattle Genetics plan to discuss the results with the U.S. Food and Drug Administration (U.S. FDA)Full data to be presented at an upcoming medical meeting Copenhagen, Denmark; June 29, 2020 – Genmab A/S (Nasdaq:...
Jun 10, 2020 06:00 am ET
Genmab and AbbVie Announce Broad Oncology Collaboration
Company Announcement Genmab and AbbVie entered into a broad collaboration to jointly develop and commercialize three of Genmab’s next-generation bispecific antibody products, including epcoritamabCompanies establish a discovery research...
Jun 04, 2020 09:42 am ET
Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma
Company Announcement Subcutaneous fixed-dosed formulation of DARZALEX® (daratumumab) approved in Europe for the treatment of adult patients with multiple myelomaApproval follows positive opinion by European Committee for Medicinal Products for...
May 28, 2020 12:14 pm ET
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
Company Announcement Phase III ANDROMEDA study of subcutaneous daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone for patients with newly diagnosed light-chain (AL) amyloidosis met the primary endpoint of patients with...
May 14, 2020 09:40 am ET
Genmab Announces Data to be Presented at the EHA25 Virtual Congress
Media Release Copenhagen, Denmark, May 14, 2020 Eight industry-sponsored abstracts featuring Genmab programs and partner programs selected for presentation at EHA25 Virtual Congress Genmab A/S (Nasdaq: GMAB) announced today that eight industry...
May 06, 2020 11:01 am ET
Genmab Announces Financial Results for the First Quarter of 2020
May 6, 2020; Copenhagen, Denmark;Interim Report for the First Quarter Ended March 31, 2020 Highlights DARZALEX® (daratumumab) net sales increased approximately 49% compared to the first quarter of 2019 to USD 937 million, resulting in royalty...
May 01, 2020 01:36 pm ET
Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma
Company Announcement Subcutaneous formulation of daratumumab, DARZALEX FASPRO™, approved by the U.S. FDA for the treatment of patients with multiple myelomaApproval based on data from Phase III COLUMBA and Phase II PLEIADES studiesIn the studies,...
Apr 30, 2020 02:55 pm ET
CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma
Company Announcement Committee for Medicinal Products for Human Use issued Positive Opinion for subcutaneous formulation of daratumumab for the treatment of patients with multiple myelomaOpinion based on data from Phase III COLUMBA and Phase II...
Apr 14, 2020 06:35 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020
Company Announcement Net sales of DARZALEX® in the first quarter of 2020 totaled USD 937 millionGenmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April 14, 2020 – Genmab A/S (Nasdaq: GMAB) announced...
Mar 10, 2020 01:09 am ET
Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer
Company Announcement Copenhagen, Denmark; March 10, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that Anthony Mancini will join the company as Executive Vice President and Chief Operating Officer, effective March 23, 2020. Mr. Mancini will be...
Feb 21, 2020 03:20 pm ET
Genmab Board of Directors Chairman to Step Down
Company Announcement Copenhagen, Denmark; February 21, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the Chairman of the Board of Directors, Mr. Mats Pettersson, B.Sc., has decided to step down from the Board at Genmab A/S’ Annual General...
Feb 19, 2020 11:05 am ET
Genmab Publishes 2019 Annual Report
Company Announcement Copenhagen, Denmark; February 19, 2020 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2019. Below is a summary of business progress in 2019, financial performance for the year and the...
Jan 22, 2020 06:32 am ET
Genmab Announces 2019 Net Sales Figures for DARZALEX® (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen
Company Announcement Net trade sales of DARZALEX in 2019 totaled USD 2,998 millionGenmab to receive milestone payment of USD 150 million in DARZALEX collaborationMilestone triggered by sales of DARZALEX reaching USD 3 billion in the calendar year...
Jan 20, 2020 12:02 pm ET
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement DARZALEX® (daratumumab) approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell...
Dec 19, 2019 10:19 am ET
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year research termGenmab will provide CureVac with a...
Dec 13, 2019 06:32 am ET
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement CHMP issued positive opinion for DARZALEX® in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell...
Dec 05, 2019 03:49 am ET
Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
Company Announcement Genmab to receive milestone payment of USD 100 Million in DARZALEX collaboration Milestone triggered by sales of DARZALEX reaching USD 2.5 billion in a calendar year Copenhagen, Denmark; December 5, 2019 – Genmab A/S (Nasdaq:...
Nov 19, 2019 11:14 am ET
Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement DARZALEX® approved in Europe in combination with lenalidomide and dexamethasone as treatment for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant Approval follows...
Nov 06, 2019 11:01 am ET
Genmab Announces Financial Results for the First Nine Months of 2019
November 6, 2019; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2019 Highlights Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol...
Oct 30, 2019 04:31 pm ET
David Eatwell to Retire as Chief Financial Officer of Genmab
Company Announcement David Eatwell has decided to retire on February 29, 2020Anthony Pagano, Senior Vice President Finance and Corporate Development will be promoted to Executive Vice President and CFO, effective March 1, 2020Genmab will assume a...
Oct 18, 2019 07:09 am ET
CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement CHMP issued a positive opinion for DARZALEX® in combination with lenalidomide and dexamethasone as treatment for newly diagnosed adult patients with multiple myeloma who are ineligible for autologous stem cell transplant Final...
Oct 15, 2019 06:47 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019
Company Announcement Net sales of DARZALEX in the third quarter of 2019 totaled USD 765 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 15, 2019 – Genmab A/S (Nasdaq: GMAB)...
Sep 26, 2019 11:43 am ET
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with bortezomib, thalidomide (an immunomodulatory agent) and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for...
Sep 13, 2019 09:40 am ET
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Company Announcement Phase III CANDOR study of daratumumab in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma met the primary endpoint of improvement in progression free survivalData to be discussed with...
Sep 13, 2019 09:04 am ET
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) versus teriflunomide in patients with relapsing multiple sclerosis (RMS) were presented at the 35th Congress of the European Committee for Treatment...
Sep 09, 2019 09:07 am ET
Genmab and Tempus Enter into Strategic Collaboration Agreement
Media Release Copenhagen, Denmark, September 9, 2019 Genmab and Tempus sign agreement to research and develop novel targets Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a strategic collaboration agreement with Tempus, a...
Aug 30, 2019 01:16 am ET
Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies
Company Announcement In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate (ARR) over teriflunomide in patients with relapsing forms of multiple sclerosis (RMS) Key secondary endpoints of delaying...
Aug 22, 2019 01:10 am ET
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
Company Announcement DARZALEX® approved in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant in JapanGenmab to receive USD 7...
Aug 14, 2019 11:00 am ET
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
August 14, 2019; Copenhagen, Denmark; Interim Report for the First Half of 2019 Highlights Registration statement filed with the U.S. Securities and Exchange Commission for the proposed public offering of American Depository Shares...
Jul 23, 2019 11:28 am ET
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Company Announcement Genmab A/S has today completed the closing of the exercise in full by the underwriters of their over-allotment option in connection with its initial public offering of American Depositary Shares in the United States and...
Jul 22, 2019 11:12 am ET
Genmab Announces the Completion of its Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Company Announcement Genmab A/S has today completed its initial public offering of American Depositary Shares in the United States and registered a capital increase of 2,850,000 ordinary shares in connection with the offering...
Jul 19, 2019 03:52 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 19, 2019 – Genmab A/S (CSE: GEN, Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed...
Jul 19, 2019 05:40 am ET
Genmab Announces Full Exercise of Underwriters’ Over-Allotment Option in Initial Public Offering
Company Announcement The 15% over-allotment option in connection with Genmab's initial public offering of American Depositary Shares in the United States and listing on the Nasdaq Global Select Market has been exercised in full Copenhagen,...
Jul 17, 2019 08:30 pm ET
Genmab Prices its Initial Public Offering of American Depositary Shares (ADSs) in the United States
Company Announcement Genmab has today announced the pricing of its initial public offering of ADSs and the listing of the ADSs on the Nasdaq Global Select Market under the symbol “GMAB”Genmab has applied to change the trading symbol of its...
Jul 16, 2019 06:44 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2019
Company Announcement Net sales of DARZALEX® in the second quarter of 2019 totaled USD 774 millionGenmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; July 16, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN)...
Jul 12, 2019 11:43 am ET
Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab
Company Announcement BLA submitted to U.S. FDA for subcutaneous formulation of daratumumabSubmission based on data from Phase III COLUMBA and Phase II PLEIADES studies Copenhagen, Denmark; July 12, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN)...
Jul 09, 2019 06:22 am ET
Genmab Commences Public Offering of American Depositary Shares (ADSs) in the United States
Company Announcement Genmab A/S has today commenced a public offering of American Depositary Shares (“ADSs”) and has filed a preliminary prospectus relating to the offeringGenmab A/S has applied for the ADSs to be listed on the Nasdaq Global Select...
Jul 08, 2019 03:24 pm ET
Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newly Diagnosed Patients with Multiple Myeloma Treated with Daratumumab in Combination with Lenalidomide
Company Announcement Topline data from the randomized Phase II GRIFFIN study in transplant eligible, newly diagnosed patients with multiple myeloma treated with daratumumab in combination with lenalidomide, bortezomib, and dexamethasone met the...
Jun 27, 2019 01:22 pm ET
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell...
Jun 26, 2019 08:30 am ET
StageZero Life Sciences Ltd Announces Initiation Of Trading Under The Stock Trading Symbol SZLS
TORONTO, ON / ACCESSWIRE / June 26, 2019 / StageZero Life Sciences Ltd (Formerly GeneNews or the "Company") (TSX: GEN) is pleased to announce that beginning today, June 26, 2019, the Company will be trading under the ticker symbol (TSX: SZLS). Trading will continue in the Company's common shares under the new name, symbol and CUSIP number. The Company officially changed its name from GeneNews Ltd. to StageZero Life Sciences Ltd on June 20th.
Jun 25, 2019 01:56 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 25, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed...
Jun 20, 2019 01:40 pm ET
GeneNews Announces Results of Annual and Special Meeting of Shareholders
TORONTO, ON / ACCESSWIRE / June 20, 2019 / GeneNews Limited ("GeneNews" or the "Company") (TSX: GEN) is pleased to report that shareholders voted in favour of all items of business, including the election of all nominee directors listed in the Company's management information circular dated May 15, 2019 (the "Circular"), at its annual and special meeting of shareholders held on June 19, 2019 (the "Meeting").
Jun 19, 2019 11:36 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 19, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed...
Jun 19, 2019 07:57 am ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 19, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed...
Jun 17, 2019 05:30 pm ET
GeneNews Will Host an Investor Call and Webcast on June 19th Following the Company's Annual General Meeting
TORONTO, ON / ACCESSWIRE / June 17, 2019 / GeneNews Limited ("GeneNews" or the "Company") (TSX: GEN) today announced that it will host a live webcast that includes an online presentation following the Company's Annual General Meeting of shareholders on Wednesday, June 19, 2019.
Jun 11, 2019 01:48 am ET
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38
Company Announcement Genmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next-generation CD38 antibody product, HexaBody®-CD38, incorporating Genmab’s proprietary HexaBody technologyNew agreement builds on Genmab’s...
Jun 10, 2019 12:20 pm ET
GeneNews Signs Global Licensing and Services Agreement with Oncore Pharma
TORONTO, ON / ACCESSWIRE / June 10, 2019 / GeneNews Limited (TSX: GEN), a life sciences company specializing in blood-based biomarker tests for early cancer detection, announced today that it has signed a Global Licensing and Services Agreement (the "Agreement") with Oncore Pharma, Inc.
May 30, 2019 05:07 pm ET
U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement U.S. FDA grants Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell...
May 28, 2019 04:32 pm ET
Genmab Files Registration Statement in the United States for a Proposed Public Offering of American Depositary Shares (ADSs) and Applies for Listing of the ADSs on Nasdaq
Company Announcement Genmab has today filed a registration statement with the U.S. Securities and Exchange Commission for the proposed public offering of ADSs and has applied for listing of the ADSs on the Nasdaq Global Select Market under the...
May 21, 2019 09:00 am ET
InvestmentPitch Media Video Discusses GeneNews' Launch of its First Awareness Campaign on Prostate Cancer Using Animated "Gary the Prostate" - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2019) - GeneNews Limited (TSX: GEN), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has launched the company's first awareness campaign on prostate cancer. The awareness program cleverly uses the animated "Gary the Prostate" to introduce viewers to the subject of prostate cancer. To view the full video and learn more about Gary's campaign go to www.mycancerrisk.info/gary.
May 16, 2019 08:30 am ET
GeneNews Announces Q1 2019 Results and Provides Progress Update
Company Launches National Marketing Campaign to Promote Telehealth Business Model, Processes First Patient-Directed Orders, In Discussions With International Distributor for ColonSentry®
May 14, 2019 03:45 pm ET
Gary the Prostate, GeneNews' Spokesperson for Prostate Cancer Awareness, Recently Diagnosed with Elevated PSA
TORONTO, ON / ACCESSWIRE / May 14, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company"), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has announced that Gary the Prostate, their national spokesperson for prostate cancer awareness has been recently diagnosed with an elevated PSA.
May 09, 2019 11:31 am ET
GeneNews Introduces Gary the Prostate to Build Awareness About Prostate Health
Company introduces Gary the Prostate to educate consumers about prostate health and prostate cancer awareness
May 08, 2019 11:01 am ET
Genmab Announces Financial Results for the First Quarter of 2019
May 8, 2019; Copenhagen, Denmark;  Interim Report for the First Quarter Ended March 31, 2019 Highlights Regulatory applications for daratumumab in combination with lenalidomide and dexamethasone based on the MAIA study in frontline multiple...
Apr 23, 2019 09:10 am ET
InvestmentPitch Media Video Discusses GeneNews and Launch of Company's First Telehealth Program for Marketing the Prostate Health Index Directly to Patients Nationwide - Video Available on Investm
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2019) - GeneNews Limited (TSX: GEN), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has launched the company's first telehealth program for marketing the Prostate Health Index (phi) directly to patients nationwide. The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign prostate conditions in men with elevated PSA.
Apr 22, 2019 08:25 am ET
The Lind Partners back GeneNews in its Quest to Detect Cancer at Stage Zero
TORONTO, ON / ACCESSWIRE / April 22, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company") announced today that Lind Asset Management XI, LLC ("Lind") has increased its funding under the First Convertible Security of the Convertible Security Funding Agreement (the "Agreement") dated May 31, 2018 between the Company and Lind by CDN$750,000 (the "Additional Funding"). The Agreement was first announced on June 1, 2018.
Apr 17, 2019 12:58 pm ET
The Prostate Health Index, a Blood Test for Prostate Cancer Detection, is Now Available to Consumers Nationwide Through GeneNews' National Telehealth Program
TORONTO, ON / ACCESSWIRE / April 17, 2019 / GeneNews Limited (TSX: GEN) ('GeneNews' or the 'Company'), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has launched the company's first telehealth program for marketing the Prostate Health Index (phi) directly to patients nationwide. The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign prostate conditions in men with elevated PSA.1 Patients can now initiate a physic
Apr 16, 2019 06:46 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019
Company Announcement Net sales of DARZALEX in the first quarter of 2019 totaled USD 629 millionGenmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April 16, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN)...
Apr 03, 2019 01:25 pm ET
GeneNews Announces Q4 2018 Results and Provides Progress Update
Company Builds Momentum with Launch of Patient Directed Cancer Testing; Gains Ground in Population Health Initiatives with Health Systems and Employers; and Plans are Underway for Validation of Next-Generation Cancer Panel - Aristotle®
Apr 03, 2019 07:33 am ET
Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma
Company Announcement Phase III study to examine daratumumab plus lenalidomide as maintenance treatment in patients with newly diagnosed multiple myelomaStudy utilizes the subcutaneous formulation of daratumumabStudy expected to start in the first...
Apr 03, 2019 07:30 am ET
CORRECTION: GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call
In the news release, "GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call", issued April 2, 2019 by GeneNews Limited over Accesswire, we are advised by the company that the time of the Conference Call has changed to Wednesday, April 3, 4:30 PM ET. The complete, corrected release follows:
Apr 02, 2019 05:10 pm ET
GeneNews Closes CDN $510,000 Second Tranche of Strategic Private Placement
TORONTO, ON / ACCESSWIRE / April 2, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company") today announced that the CDN $510,000 second tranche of the private placement financing has closed.
Apr 02, 2019 07:30 am ET
CORRECTION: GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call
In the news release, "GeneNews Announces Fourth Quarter 2018 Results and Year End Investor Call", issued Friday, March 29, 2019 by GeneNews Limited over Accesswire, we are advised by the company that the date of the Conference Call has changed to Wednesday, April 3, 8:30 AM ET. The complete, corrected release follows:
Mar 29, 2019 11:00 am ET
Mar 28, 2019 08:55 am ET
GeneNews Launches First Telehealth Initiative for Patient Directed Testing
Company to Capitalize on $16.7 Billion Telehealth Market by Offering Patient Directed Testing Through an Independent Provider Network
Mar 27, 2019 05:12 am ET
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous...
Mar 26, 2019 09:20 am ET
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement sBLA submitted to U.S. FDA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell...
Mar 25, 2019 01:50 pm ET
GeneNews Closes First Tranche of $1.0 Million Strategic Private Placement
TORONTO, ON / ACCESSWIRE / March 25, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company") today announced the closing of a $1.0 million strategic private placement financing round and, due to high demand, have launched and expect to close a second tranche by March 29, 2019.
Mar 22, 2019 06:48 am ET
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment for newly diagnosed multiple myeloma patients who are not candidates for high dose chemotherapy...
Feb 25, 2019 11:47 am ET
Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab
Company Announcement Phase III COLUMBA study comparing the subcutaneous formulation of daratumumab to the intravenous formulation in patients with relapsed or refractory multiple myeloma met both co-primary endpoints Results show that daratumumab...
Feb 20, 2019 11:18 am ET
Genmab 2018 Annual Report
Company Announcement Copenhagen, Denmark; February 20, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2018.  Below is a summary of business progress and financial performance for the year, and financial outlook...
Jan 31, 2019 11:36 am ET
Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
Company Announcement Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEXOn January 25, 2019, a summary judgement decision ruled that the three MorphoSys patents were...
Jan 28, 2019 06:30 am ET
GeneNews Publishes Data on ColonSentry® in Colorectal Cancer Risk Assessment
Study demonstrates validity of blood-based biomarker test as an adjunct method to colon cancer screening tests in non-compliant patient populations
Jan 28, 2019 06:30 am ET
GeneNews Publishes Data on ColonSentry® in Colorectal Cancer Risk Assessment
Study demonstrates validity of blood-based biomarker test as an adjunct method to colon cancer screening tests in non-compliant patient populations
Jan 26, 2019 09:14 am ET
Genmab Announces that the patents asserted against DARZALEX® in the United States have been declared invalid by summary judgment.
Company Announcement Patents asserted against Janssen Biotech, Inc. & Genmab in the United States have been declared invalid by summary judgment Copenhagen, Denmark; January 26, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the...
Jan 22, 2019 10:57 am ET
Genmab Announces Initiation of U.S. FDA Regulatory Submission for Label Expansion of Daratumumab in Combination with Lenalidomide and Dexamethasone in Front Line Multiple Myeloma
Company Announcement First part of regulatory package submitted to the U.S. FDA for label expansion of daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are not candidates for...
Jan 22, 2019 06:44 am ET
Genmab Announces 2018 Net Sales Figures for DARZALEX® (Daratumumab)
Company Announcement Net sales of DARZALEX in 2018 totaled USD 2,025 millionGenmab receives royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 22, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that...
Jan 17, 2019 01:37 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; January 17, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has...
Jan 11, 2019 02:13 pm ET
GeneNews Closes Funding for Second Convertible Security Funding Agreement with Lind Asset Management
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Jan 08, 2019 12:34 pm ET
Genmab Achieves USD 75 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen
Company Announcement Genmab to receive milestone payment of USD 75 million in DARZALEX collaborationMilestone triggered by sales of DARZALEX reaching USD 2 billion in a calendar year Copenhagen, Denmark; January 8, 2019 – Genmab A/S (Nasdaq...
Dec 28, 2018 08:10 am ET
GeneNews Expands Coverage by Commercial Health Insurance Networks
Signs Second Convertible Security Funding Agreement with Lind Asset Management for $500,000
Dec 13, 2018 08:58 pm ET
Genmab Announces Submission of Supplemental New Drug Application for Daratumumab in Front Line Multiple Myeloma in Japan
Company Announcement Supplemental new drug application submitted in Japan for daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem...
Nov 15, 2018 07:03 am ET
/C O R R E C T I O N from Source -- GeneNews Limited/
In the news release, GeneNews Announces Q3 2018 Results and Provides Progress Update, issued 15-Nov-2018 by GeneNews Limited over Cision, we are advised by the company that the third paragraph should be replaced with what follows below, rather than as originally issued inadvertently. The complete, corrected release follows:
Nov 15, 2018 07:03 am ET
Nov 14, 2018 11:00 am ET
Genmab Announces Financial Results for the First Nine Months of 2018
November 14, 2018; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2018 Highlights USD 1,441 million in net sales of DARZALEX® (daratumumab), resulting in royalty income of DKK 1,111 millionDARZALEX approved in...
Nov 13, 2018 04:17 pm ET
GeneNews Announces Third Quarter 2018 Results Investor Call
Conference Call – 8:30am Thursday, November 15thNew Website and Investor Presentation Now Live at GeneNews.Com
Nov 13, 2018 04:17 pm ET
GeneNews Announces Third Quarter 2018 Results Investor Call
Conference Call – 8:30am Thursday, November 15thNew Website and Investor Presentation Now Live at GeneNews.Com
Oct 29, 2018 04:52 pm ET
Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
Company Announcement Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone in front line multiple myeloma met the primary endpoint (PFS) at a pre-planned interim analysis demonstrating the superiority of DRd over...
Oct 21, 2018 05:46 pm ET
Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
Company Announcement Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone in front line multiple myeloma met the primary endpoint of stringent Complete Response (sCR) after induction and...
Oct 16, 2018 06:45 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2018
Company Announcement Net sales of DARZALEX in the third quarter of 2018 totaled USD 498 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; October 16, 2018 – Genmab A/S (Nasdaq Copenhagen:...
Oct 08, 2018 06:50 pm ET
Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress
Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that updated clinical data from the innovaTV 201 Phase II study evaluating tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer will be presented as a poster at the European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich, Germany from October 19 to 23, 2018. Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) designed to target the Tissue Factor antigen, which is expressed on a broad
Sep 24, 2018 08:30 am ET
GeneNews Announces Resignation of Leslie Auld as CFO and Director and Appointment of Warren Whitehead as Chief Accountant.
TORONTO, Sept. 24, 2018 /CNW/ - GeneNews Limited (TSX:GEN) ("Gene-News" or the "Company") today announced the resignation of Leslie Auld as Chief Financial Officer (CFO) and Director, and the appointment of Warren Whitehead as Chief Accountant. Ms. Auld is leaving to pursue another opportunity.
Sep 24, 2018 08:30 am ET
GeneNews Announces Resignation of Leslie Auld as CFO and Director and Appointment of Warren Whitehead as Chief Accountant.
TORONTO, Sept. 24, 2018 /PRNewswire/ - GeneNews Limited (TSX:GEN) ("Gene-News" or the "Company") today announced the resignation of Leslie Auld as Chief Financial Officer (CFO) and Director, and the appointment of Warren Whitehead as Chief Accountant. Ms. Auld is leaving to pursue another opportunity.
Sep 18, 2018 12:16 pm ET
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement Copenhagen, Denmark; September 18, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 18,414 shares as a consequence of the exercise of employee warrants. The increase is effected without any...
Aug 31, 2018 08:35 am ET
Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Front Line Multiple Myeloma
Company Announcement DARZALEX approved in Europe in combination with bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myelomaApproval follows positive opinion by European Committee for Medicinal...
Aug 15, 2018 07:30 am ET
GeneNews Announces Q2 2018 Results and Provides Progress Update
Closed on the first tranche of the Unit private placement for C$1.2 million and the Lind convertible security for C$2 million Number of enrolled and active practices continues to grow Implementation planning continues with several large healthcare systems, with test initiation planned for Q3/Q4. High Risk Population and Direct to Consumer testing continues to be built out, as does new agreements with supportive diagnostic labs to cross-promote as well as expand testing to each other's client base. Approximately 1500 tests processed during the quarter. Subsequent to the Quarter:
Aug 15, 2018 07:30 am ET
GeneNews Announces Q2 2018 Results and Provides Progress Update
Closed on the first tranche of the Unit private placement for C$1.2 million and the Lind convertible security for C$2 million Number of enrolled and active practices continues to grow Implementation planning continues with several large healthcare systems, with test initiation planned for Q3/Q4. High Risk Population and Direct to Consumer testing continues to be built out, as does new agreements with supportive diagnostic labs to cross-promote as well as expand testing to each other's client base. Approximately 1500 tests processed during the quarter. Subsequent to the Quarter:
Aug 15, 2018 07:00 am ET
GeneNews and LifeX™ Partner to Deliver Proprietary "Liquid Biopsy" Molecular Diagnostics to Health Systems to Detect Cancer at Earliest Stages
TORONTO, Aug. 15, 2018 /CNW/ - GeneNews Limited (TSX: GEN), an innovator in the liquid biopsy space, today announced a partnership with Pittsburgh-based, LifeX™, a strategic engine for developing and nurturing cutting-edge, life-saving health solutions and bringing these innovations to market.
Aug 15, 2018 07:00 am ET
GeneNews and LifeX™ Partner to Deliver Proprietary "Liquid Biopsy" Molecular Diagnostics to Health Systems to Detect Cancer at Earliest Stages
TORONTO, Aug. 15, 2018 /PRNewswire/ - GeneNews Limited (TSX: GEN), an innovator in the liquid biopsy space, today announced a partnership with Pittsburgh-based, LifeX™, a strategic engine for developing and nurturing cutting-edge, life-saving health solutions and bringing these innovations to market.
Aug 13, 2018 10:32 pm ET
/C O R R E C T I O N from Source -- GeneNews Limited/
In the news release, GeneNews Second Quarter 2018 Operating and Financial Results, issued 10-Aug-2018 by GeneNews Limited over Cision, we are advised by the company that the date of the Conference Call has changed to Wednesday, August 15, 8:30 AM ET. The complete, corrected release follows:
Aug 13, 2018 10:32 pm ET
/C O R R E C T I O N from Source -- GeneNews Limited/
In the news release, GeneNews Second Quarter 2018 Operating and Financial Results, issued 10-Aug-2018 by GeneNews Limited over Cision, we are advised by the company that the date of the Conference Call has changed to Wednesday, August 15, 8:30 AM ET. The complete, corrected release follows:
Aug 10, 2018 09:18 am ET
GeneNews Second Quarter 2018 Operating and Financial Results
Conference Call – 8:30am Tuesday, August 14th
Aug 10, 2018 09:18 am ET
GeneNews Second Quarter 2018 Operating and Financial Results
Conference Call – 8:30am Tuesday, August 14th
Aug 09, 2018 12:18 pm ET
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; August 9, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 29 of the Danish Securities Trading Act that...
Aug 08, 2018 11:02 am ET
Genmab Announces Financial Results for the First Half of 2018
August 8, 2018; Copenhagen, Denmark; Interim Report for the First Half of 2018 Highlights USD 943 million in net sales of DARZALEX® (daratumumab), resulting in royalty income of DKK 695 millionU.S. FDA approved DARZALEX (daratumumab) in...
Jul 27, 2018 08:28 am ET
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma
Company Announcement CHMP issued positive opinion for DARZALEX for front line multiple myelomaFinal decision from European Commission expected in the coming monthsOpinion based on data from Phase III ALCYONE study Copenhagen,...
Jul 17, 2018 06:50 am ET
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2018
Company Announcement Net sales of DARZALEX in the second quarter of 2018 totaled USD 511 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; July 17, 2018 – Genmab A/S (Nasdaq...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.